Bristol Myers Squibb and BioNTech Announce $11 Billion Cancer Drug Partnership
Originally Published 7 months ago — by Financial Times
Bristol Myers Squibb has signed an $11 billion partnership with BioNTech to develop and commercialize BNT327, a promising cancer drug that could rival Keytruda, with potential to treat up to 3 million patients and transform cancer care. The deal includes shared clinical trial costs and milestone payments, reflecting the drug's significant potential in immunoncology.